ORLANDO, Florida, May 6th, 2020– Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered GMP manufacturing facility specialized in the research, development, and manufacturing of cell-based therapies, is pleased to announce a collaboration with NeoProgen, Inc.
NeoProgen, a Baltimore-based company led by Medtech entrepreneur Bill Niland, is a preclinical stage therapeutics company specializing in the development of novel cellbased cardiac therapies for heart regeneration. Similar to Mr. Niland’s earlier venture with Harpoon Medical, NeoProgen has origins in research at the University of Maryland, Baltimore. That is where Dr. Sunjay Kaushal, a leading pediatric cardiac surgeon, discovered that a specific kind of neonatal cardiac progenitor/ stem cells (nCPCs), obtained from discarded cardiac tissue biopsies, are extremely effective in regenerating muscle tissue in the heart.
Under the terms of the agreement, Aspire is responsible for the cGMP manufacturing of a clinical-grade Master Cell Bank from immortalized clonal isolate derived from human neonatal cardiac stem/progenitor cells for NeoProgen. Using this Master Cell Bank, the Company will also manufacture specific cell and cell-free (secretome) based therapies for future clinical trials.
“We are excited to work with the Aspire team. It is clear that through working together with this specialized CDMO, we are on the path to developing a well-characterized, scalable, and sustainable process for our cell-based therapies.” says Bill Niland.
Aspire has developed and manufactured cell-based therapies for both FDA and Health Canada clinical trials across multiple cell types. The research and development team has extensive experience in process development and cGMP manufacturing.
“We collaborate with clients and offer assistance in each step required to transition the therapy from the bench-side to a scalable clinical-grade therapy. Our goal is to help create a manufacturing process specific to client needs that will prioritize quality, cost of goods, and sustainability, resulting in a commercially viable product.” Says Nermin Gerges, PhD, General Manager of Aspire Health Science, LLC.
ABOUT ASPIRE HEALTH SCIENCE, LLC
Aspire Health Science, LLC is an FDA registered manufacturing facility specialized in development and manufacturing of cell-based therapies.
Kingsman Scientific Management Inc. provides both strategic and high-level project management to support and accelerate development of novel technologies.
CONTACT INFORMATION:
Kyle Makofka, President and CEO
Aspire Health Science, LLC
Tel: (407) 420-7246
info@aspire2cure.com
investorrelations@aspire2cure.com
www.aspire2cure.com